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Abstract
Background: Diabetes significantly increases the risk of morbidity and mortality associated with surgery.
These guidelines target anesthetists, providing guidelines for management of the diabetic patients in the
pre-operative, peri-operative and post-operative periods. Methods: The following paper summarizes the
Association of Anaesthetists of Great Britain and Ireland clinical guidelines on peri-operative
management of the surgical patients with diabetes 2015. Results: It is recommended that where possible
all diabetic patients achieve an HbA1c less than 69 mmol/mol (8.5%) prior to surgery. On the day of
surgery, fasting periods should be limited to one meal and if this is not possible, a variable-rate
intravenous insulin infusion should be started. Intra-operatively blood glucose should remain between 6
and 10 mmol/L. Post-operatively, the key to resuming normal diabetic management is through returning
to an normal diet as soon as possible. Conclusions: The aim of management of a diabetic patient during
the operative period is to maintain normal blood glucose levels (6 - 10 mmol/L). This is achieved through
careful pre-operative planning, appropriate management of blood glucose levels and fluid balance intraoperatively and a smooth transition to resume the patients normal diabetic management.

Publication Details
White, L. (2016). Peri-operative management of the surgical patient with diabetes: a guideline summary.
Journal of Endocrinology and Metabolism, 6 (3), 97-99.

This journal article is available at Research Online: https://ro.uow.edu.au/smhpapers/4116

Elmer

Meeting Summary

ress

J Endocrinol Metab. 2016;6(3):97-99

Peri-Operative Management of the Surgical Patient With
Diabetes: A Guideline Summary
Leigh White

Abstract
Background: Diabetes significantly increases the risk of morbidity
and mortality associated with surgery. These guidelines target anesthetists, providing guidelines for management of the diabetic patients
in the pre-operative, peri-operative and post-operative periods.
Methods: The following paper summarizes the Association of Anaesthetists of Great Britain and Ireland clinical guidelines on peri-operative management of the surgical patients with diabetes 2015.
Results: It is recommended that where possible all diabetic patients
achieve an HbA1c less than 69 mmol/mol (8.5%) prior to surgery.
On the day of surgery, fasting periods should be limited to one meal
and if this is not possible, a variable-rate intravenous insulin infusion
should be started. Intra-operatively blood glucose should remain between 6 and 10 mmol/L. Post-operatively, the key to resuming normal
diabetic management is through returning to an normal diet as soon
as possible.
Conclusions: The aim of management of a diabetic patient during
the operative period is to maintain normal blood glucose levels (6 10 mmol/L). This is achieved through careful pre-operative planning,
appropriate management of blood glucose levels and fluid balance
intra-operatively and a smooth transition to resume the patients normal diabetic management.
Keywords: Diabetes; Peri-operative; Anesthesia

2015 [1]. Diabetes significantly increases the risk of morbidity
and mortality associated with surgery. The poor outcomes associated with diabetes is related to hypoglycemia and hyperglycemia, complex polypharmacy, increased infection rates,
microvascular and macrovascular co-morbidities and insulin
prescribing errors [2-8]. These guidelines target anesthetists,
providing guidelines for management of the diabetic patients
in the pre-operative, peri-operative and post-operative periods.

Primary Care and Surgical Outpatient Clinic
It is recommended that all patients undergoing elective surgery
should have an HbA1c less than 69 mmol/mol (8.5%). This
should be addressed at the time of referral for elective surgery.
When assessed in the surgical outpatient clinic, there should
be a recorded HbA1c less than 69 mmol/mol within 3 months
leading up to the surgery. If this has not been achieved, then
the surgery should be delayed to allow for better control. If this
is not achievable such as in the presence of chronic infection
or steroid treatment, the surgery should proceed with all risks
explained to the patient. The risks include a 50% increase in
mortality and two to three times the risk of surgical site infections, respiratory infections, myocardial infarction and acute
kidney injury [2]. In addition to glycemic control, it is important for the outpatient surgical team to have access to information regarding type of diabetes, duration, complications and
current management.

Pre-Operative Assessment and Management

Introduction
The following paper summarizes the Association of Anaesthetists of Great Britain and Ireland clinical guidelines on perioperative management of the surgical patients with diabetes
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The pre-operative assessment should occur well in advance to
1) optimize glycemic control and 2) ensure all investigations
are performed to assess co-morbidities. This recommendation
is backed by the National Institute for Health and Care Excellence (NICE) guidance on peri-operative testing [9]. At this
time, the patient should be educated on the impact of the preoperative, peri-operative and post-operative periods on glycemic control.
It is recommended that the patient be for day surgery with
minimal fasting time, whilst maintaining euglycemia (6 - 10
mmol/L). Pre-operatively if the patient is expected to only
miss one meal, this may be facilitated through alterations to
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their current diabetes management. Patients should also be advised to carry a source of glucose during the fasting period
and that they are likely to experience erratic glycemic control
following the surgery.
During the fasting period, the aim is to avoid hyperglycemia and hypoglycemia. There are specific recommendations
for insulin and oral hypoglycemic agents in the context of a
short (one meal missed) fasting period. Once daily long acting insulins whether given the night before or on the day of
surgery should be reduced by 20% and blood glucose levels
(BGLs) should be checked on admission. If a variable rate intravenous insulin infusion (VRIII) is used, it should continue at
80% of the patients usual insulin dose. In patients using a twice
daily biphasic or short acting insulin, there should be no dose
adjustment the day prior to surgery. On the morning of surgery,
half the calculated total dose should be given as an intermediate acting insulin. In patients on short acting insulin given
three to five times per day, there should be no change in dose
the night before. On the morning of surgery, the basal insulin
should remain unchanged with bolus insulin omitted. All oral
hypoglycemic agents should be taken as normal the night prior
to surgery. On the day of surgery, metformin, GLP-1 analogues
and pioglitazone should be taken as normal, unless the surgery
requires contrast media in the case of metformin. Medications
that should be withheld on the day of surgery include sulphonylureas, meglitinides and acarbose. The only medication requiring dose changes is SGLT-2 inhibitors, which are reduced
by 50%. If a VRIII is being used all medications should be
withheld, with the exception of GLP-1 inhibitors which can be
taken as normal. It is recommended that VRIII should be used
in patients who miss more than one meal, those with type-1
diabetes, those with poorly controlled diabetes (HbA1c > 69
mmol/mol) and those that require emergency surgery.

of choice. The rate of infusion should be 25 - 50 mL/kg/day to
meet normal maintenance requirement. If non-hypervolemic
hyponatremia occurs, the fluid of choice is either glucose 5%
in 0.9% saline with 0.15% potassium or glucose 5% in 0.9%
saline with 0.3% potassium. The addition of a balanced isotonic solution may be used for optimal fluid balance.

Intra-Operative Care and Monitoring

Diabetes and Emergency Surgery

It is recommended that BGLs should be measured before
and regularly during a surgery aiming for a target range of
6 - 10 mmol/L. Diabetic ketoacidosis should be treated for if
BGLs exceed 12 mmol/L and blood ketones are greater than 3
mmol/L (or urine ketones > 2+ on dipstick). If hyperglycemia
and not DKA is present intra-operatively, the patient should
be managed with subcutaneous rapid acting insulin (no more
than 6 IU). The BGL should be checked hourly and only given
a second dose of insulin after 2 h. Initiation of a VRIII should
only be considered in a type-2 diabetic who remains hyperglycemic. It is recommended that hypoglycemia of 4 - 6 mmol/L
be treated with 50 mL of 20% glucose and if the BGL is < 4
mmol/L, then 100 mL of 20% glucose should be given.

It is recommended that a VRIII should be used in the setting of
an emergency surgery, unless there is concurrent DKA, which
would require a fixed rate intravenous insulin infusion. The
target BGL range of 6 - 10 mmol/L remains the same. Emergency surgery in the context of DKA should be carefully considered and the decision making process should include the
anesthetists, surgeons, intensivists and diabetologists. Intraoperatively a fixed rate insulin infusion should be used, and
this requires regular blood glucose monitoring and the administration of 20% glucose if BGLs fall below 14 mmol/L. In
addition to the insulin infusion, where possible, long acting
insulins should also be continued at 80% normal dose. The
resuscitation fluid of choice is either Hartmann’s solution or
normal saline with pre-mixed potassium chloride.

Fluid Management

It is recommended that patients with a new or changed intraoperative insulin regiment be consulted on by a specialist diabetes team. Once a normal diet is resumed, oral hypoglycemic
agents may be restarted. The exception is metformin, which
should be withheld until estimated glomerular filtration rate
exceeds 50 mL/min/1.73 m2. A VRIII in a type-1 patient needs
to continue until 30 - 60 min after the first dose of subcutaneous insulin. Recommencement of subcutaneous insulin may
require dose adjustment for food intake, post-operative stress
or infection. The restarting of subcutaneous insulin must be
prior to a meal.

Other Anesthetic Considerations
It is recommended that the use of dexamethasone be carefully
considered due to the risk of hyperglycemia. If used, BGLs
should be measured hourly for 4 h after administration. The
use of regional anesthesia should also be carefully considered,
as diabetic patients are at higher risk of developing epidural
abscesses, hemodynamic instability (if autonomic neuropathy
is present) and post-nerve block neuropathy.

Safety

In patients without a VRIII, Hartmann’s solution is the fluid of
choice to avoid hyperglycemia and hyperchloremic metabolic
acidosis. In patients with VRIII, it is recommended that glucose 5% in saline 0.45% or potassium 0.3% be the initial fluid
98

Resuming “Normal” Medication and Diet PostOperation

Insulin is one of the top five high risk medications due to the
number of preparations, errors in prescribing and administration. Specifically, VRIIIs are associated with hyperglycemia,
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hypoglycemia, hyponatremia and ketosis on cessation. It is advised that patients on VRIIIs have hourly BGLs and that cessation in type-1 diabetics does not occur without overlapping
subcutaneous insulin therapy.
It is recommended that metformin only be withheld preoperatively and peri-operatively if the patient has or is at risk
of acute kidney injury. Due to the risk of lactic acidosis metformin should only be resumed once estimated glomerular filtration rate exceeds 50 mL/min/1.73 m2.

2.

3.

4.

Conclusions
The aim of management of a diabetic patient during the operative period is to maintain normal blood glucose levels (6
- 10 mmol/L). This is achieved through careful pre-operative
planning, appropriate management of blood glucose levels and
fluid balance intra-operatively and a smooth transition to resume the patients normal diabetic management.
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